Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Neurologica Belgica
Published in: Acta Neurologica Belgica 3/2017

01-09-2017 | Letter to the Editor

Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer

Authors: G. Turine, A. Peeters, C. Hermans, S. Eeckhoudt, T. Duprez

Published in: Acta Neurologica Belgica | Issue 3/2017

Login to get access

Excerpt

Effective anticoagulation is a contraindication for intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA). We here report our first and successful experience of systemic thrombolysis a few minutes after reversal of dabigatran by idarucizumab. …
Literature
1.
Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467–1507CrossRefPubMed
2.
Diener HC, Bernstein R, Butcher K, Campbell B, Cloud G, Davalos A, Davis S, Ferro JM, Grond M, Krieger D, Ntaios G, Slowik A, Touzé E (2017) Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion. Int J Stroke 12:9–12CrossRefPubMed
3.
4.
Gawehn A, Ayari Y, Heuschkel C, Kaste M, Kermer P (2016) Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report. J Med Case Rep 10:269CrossRefPubMedPubMedCentral
5.
Berrouschot J, Stoll A, Hogh T, Eschenfelder CC (2016) Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke 47:1936–1938CrossRefPubMed
Metadata
Title
Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer
Authors
G. Turine
A. Peeters
C. Hermans
S. Eeckhoudt
T. Duprez
Publication date
01-09-2017
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 3/2017
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-017-0751-5

Other articles of this Issue 3/2017

Acta Neurologica Belgica 3/2017 Go to the issue

Letter to the Editor

Caution! Self-supplementation may be injurious to your health

Erratum

Erratum to: Subacute onset Hirayama disease with extensive myelopathy on MRI in flexed posture

Abstracts

Symposium “Brain plasticity in epilepsy”, Leuven, Belgium, 13–16 May 2017

Review

The potential roles of dopamine in malignant glioma

Letter to the Editor

Subacute onset Hirayama disease with extensive myelopathy on MRI in flexed posture

Original Article

Role of infarct location and pre-existing depression on cardiac baroreceptor sensitivity in subacute ischemic stroke